.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, individuals along with metastatic stomach cysts that obtained biomarker-matched treatments based upon distributing lump DNA profiling presented a better professional perk than those acquiring unmatched treatment.